Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Axillary dissection

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    53 result(s) found for: Axillary dissection. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2005-004429-25 Sponsor Protocol Number: TS-001-DK Start Date*: 2006-10-31
    Sponsor Name:Viborg Sygehus
    Full Title: A single cohort, open trial to evaluate the efficacy and safety of TachoSil in prevention of seroma formation following axillary lymph node dissection in women following surgery for breast cancer. ...
    Medical condition: Seroma formation in the axilla following axillary dissection of lymphnodes following surgery for breast cancer in women
    Disease: Version SOC Term Classification Code Term Level
    7.1 10040102 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004337-27 Sponsor Protocol Number: ICO-A-2015-03 Start Date*: 2016-05-09
    Sponsor Name:Institut de Cancérologie de l'Ouest
    Full Title: Evaluation of the impact of a Sandostatin injection before axillary node dissection on lymphorrhea in patients operated for breast cancer
    Medical condition: The population includes all patients who must have an axillary node dissection for non-metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-001557-46 Sponsor Protocol Number: 01 Start Date*: 2012-06-27
    Sponsor Name:Sydvestjysk Sygehus, Esbjerg [...]
    1. Sydvestjysk Sygehus, Esbjerg
    2. Odense Universitetshospital
    Full Title: Perioperativ installation of ropivacain in mastectomy – with or without axillary lymph node dissection after sentinel node diagnostics or known lymph node metastasis – A double-blind, randomized cl...
    Medical condition: Unilateral mastectomy with or without axillary lymph node dissection
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000100-41 Sponsor Protocol Number: B-AP-ICG-IV Start Date*: 2013-02-28
    Sponsor Name:Jules Bordet Institute
    Full Title: Histological study of the (intravenously injected) Indocyanine Green (ICG) distribution in tumour bearing breasts and in axillary pieces of dissection
    Medical condition: breast cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005219-98 Sponsor Protocol Number: PH3-01 Start Date*: 2012-10-08
    Sponsor Name:Galena Biopharma, Inc
    Full Title: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)
    Medical condition: Operable early-stage, node-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10071113 Node-positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005289-31 Sponsor Protocol Number: LF-PB/14/05 Start Date*: 2015-08-04
    Sponsor Name:CHEMI S.P.A.
    Full Title: A multicentre, double blind, randomized placebo controlled trial to assess the effect of LF-PB on seroma formation in women with breast cancer undergoing Axillary Lymph Node Dissection
    Medical condition: Woman with Breast Cancer Undergoing Axillary Lymph Node Dissection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004496-12 Sponsor Protocol Number: BR-ICG-IV-NACT Start Date*: 2013-12-05
    Sponsor Name:Institut Jules Bordet
    Full Title: Study of the (intravenously injected) ICG distribution in tumour bearing breasts and in axillary pieces of dissection of patients who have received neo-adjuvant therapy for histologically proven ma...
    Medical condition: imaging of tumours and their margins after intravenous injection of Indocyanine Green to breast cancer patients
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-009418-42 Sponsor Protocol Number: INT-07/09 Start Date*: 2009-05-19
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study evaluating efficacy and tolerability of Sorafenib in the treatment of iatrogenic lymphedema occurring in breast cancer patients following surgical dissection of, and/or radiotherapy ...
    Medical condition: Breast cancer patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002222-70 Sponsor Protocol Number: Lidobreast Start Date*: 2013-11-15
    Sponsor Name:University Medical Centre St Radboud
    Full Title: Pilot study: Targeting the inflammatory response after breast cancer surgery with lidocaïne and dexamethasone
    Medical condition: Breast cancer patients who undergo surgery for treatment.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004872-17 Sponsor Protocol Number: IC2020-04 Start Date*: 2021-03-18
    Sponsor Name:INSTITUT CURIE
    Full Title: A Double-blind Randomized non-inferiority Trial of erector spinae block (ESP) versus paravertebral block (PVB) before Breast Cancer Surgery: Effects on acute Postoperative Pain
    Medical condition: Nervous Block erector spinae plane (ESP) or paravertebral block (PVB) preoperatively in women with breast adenocarcinoma without metastasis or breast in situ adenocarcinoma to by treated either by...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004867 10003034 Application site anesthesia LLT
    20.0 100000004864 10006290 Breast and nipple neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001128-11 Sponsor Protocol Number: BO20289 Start Date*: 2007-12-14
    Sponsor Name:F. Hoffmann-La Roche Ltd, Pharmaceuticals Divison, PDR
    Full Title: An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer.
    Medical condition: Early primary invasive adenocarcinoma of the breast (triple negative and/or basel-like phenotype)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006291 Breast neoplasms malignant and unspecified (incl nipple) HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) AT (Completed) NL (Completed) BE (Completed) CZ (Completed) GR (Completed) FI (Completed) DE (Completed) IT (Completed) ES (Completed) PT (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-005666-36 Sponsor Protocol Number: IBCSG 22-00 Start Date*: 2009-12-07
    Sponsor Name:International Breast Cancer Study Group
    Full Title: Low-dose Cytotoxics as “Anti-angiogenesis Treatment” following Adjuvant Induction Chemotherapy for Patients with ER-negative and PgR-negative Breast Cancer Maintenance Chemotherapy in Hormone Non-...
    Medical condition: Histologically proven ER-negative and PgRnegative breast cancer with either a total mastectomy with axillary clearance or a lesser procedure with axillary lymph node dissection or sentinel node pro...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000709-18 Sponsor Protocol Number: T2017-7 Start Date*: 2018-07-02
    Sponsor Name:Bernhoven
    Full Title: The effect of erector spinae block on postoperative pain and opioid use in patients undergoing breast cancer surgery with sentinel node dissection
    Medical condition: Patients undergoing unilateral (modified) mastectomy with sentinel node dissection for breast cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001974-10 Sponsor Protocol Number: CA184-029 Start Date*: 2009-03-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, doubleblind Phase 3 trial of the EORT...
    Medical condition: High Risk Stage III melanoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) SE (Completed) FI (Completed) CZ (Completed) DK (Completed) DE (Completed) ES (Completed) FR (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004319-29 Sponsor Protocol Number: 20120283 Start Date*: 2013-05-03
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared with Trastuzumab in Subjects with HER2 Positive Early Breast Cancer
    Medical condition: HER2 Positive Early Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) SK (Completed) IT (Completed) CZ (Completed) ES (Completed) GR (Completed) BG (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-000114-10 Sponsor Protocol Number: LF-PB/11/04 Start Date*: 2012-10-09
    Sponsor Name:CHEMI S.P.A.
    Full Title: A Randomized, Double-Blind, Double Dummy, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of LF-PB 10 mg, 20 mg, and 30 mg to Treat Lymphorrhea Post Axillary Dissection in Breast ...
    Medical condition: Patient undergoing breast surgery with axillary lymph node dissection.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018795-24 Sponsor Protocol Number: APREC S-2010-01 Start Date*: 2010-06-01
    Sponsor Name:Alliance pour la recherche en cancérologie
    Full Title: Evaluation of the effect of pasireotide LAR administration in the lymphocele prevention after axillary node dissection for breast cancer
    Medical condition: BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004263-35 Sponsor Protocol Number: CFEM345D2411 Start Date*: 2006-03-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomised multi-center Phase IIIb, open label, study of letrozole vs anastrazole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer
    Medical condition: This study will be a head to head comparison of letrozole versus anastrozole in the adjuvant treatment of high risk patients. Post-menopausal patients who recently have undergone their primary surg...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) AT (Completed) DK (Completed) BE (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005574-38 Sponsor Protocol Number: IJB-SUR-DESIGN-2015 Start Date*: 2016-03-17
    Sponsor Name:Institut Jules Bordet
    Full Title: The DESIGN trial A randomised, Double-blind, placEbo-controlled Study to assess the effectIveness of pectoral nerves block (Pecs) after breast surGery on Piritramide coNsumption.
    Medical condition: Locoregional analgesia in breast surgery (either conservative or non-conservative breast surgery associated with axillary dissection).
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10054799 Perioperative analgesia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005178-23 Sponsor Protocol Number: BR-TUM-ICG-IV Start Date*: 2014-01-30
    Sponsor Name:Jules Bordet Institute
    Full Title: Study of the (intravenously injected) Indocyanine Green distribution in the margins of breast cancer after tumorectomy
    Medical condition: Imaging of tumours and their margins after intravenous injection of Indocyanine Green to breast cancer patients
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 14:13:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA